Why people switch
Most switches happen for one of four reasons: needles, side effects, supply, or cost. Someone who has done well on an injection but dreads the weekly ritual may want a tablet. Someone who has plateaued on a tablet may want the stronger dual-receptor option. Neither direction is a failure, and neither is a step down — they are different molecules delivered in different ways, with different demands on your daily routine.
What matters is that the changeover is planned. Stopping one medicine and starting the other at a matching number is the single most common mistake, and it is the one most likely to produce a week of nausea or an unnecessary loss of appetite control.
How the two medicines differ
| Mounjaro | Wegovy tablets | |
|---|---|---|
| Active ingredient | Tirzepatide | Semaglutide (oral) |
| Receptors | GIP and GLP-1 | GLP-1 only |
| Format | Pre-filled injection pen | Tablet |
| Frequency | Once weekly | Once daily |
| Timing rules | Any time of day, same day each week | Empty stomach, 30 minutes before food or drink |
| Storage | Fridge, 2-8°C | Room temperature, in the blister |
| Trial average loss | About 20.9% over 72 weeks (SURMOUNT-1) | About 13.6% over 64 weeks (OASIS 4) |
| Missed dose | Take within 4 days, otherwise skip | Skip it and take the next one as normal |
The practical difference people underestimate is the timing rule. A weekly injection asks for thirty seconds of attention once a week. A daily tablet asks you to protect a thirty-minute window before your first food or drink of the day, every day. If your mornings are unpredictable, absorption becomes unpredictable too, and so do your results.
One point worth holding on to before you compare the numbers: the two medicines have never been tested against each other in a trial. The figures above come from separate studies in different groups of people over different lengths of time.
Wegovy tablets vs Mounjaro: how to chooseRoutines, trial results, side effects and NHS access compared.→
Treatment · Wegovy TabletsOral semaglutide, taken once daily on an empty stomach. Read the dosing rules and what the trials found.Learn more →
Switching from Mounjaro to the Wegovy pill
Tirzepatide has a half-life of around five days, so it clears slowly. A prescriber will normally have you take the first tablet seven days after your last injection — the day the next injection would have been due. This avoids stacking two appetite-suppressing medicines while also avoiding a gap long enough for hunger to come roaring back.
| Your Mounjaro dose | Usual tablet starting dose | Next review |
|---|---|---|
| 2.5mg or 5mg | Lowest tablet strength | After 4 weeks |
| 7.5mg or 10mg | Lowest tablet strength | After 4 weeks |
| 12.5mg or 15mg | Lowest or second tablet strength, prescriber-led | After 4 weeks |
Even at the top of the injection ladder you are unlikely to start at the top of the tablet ladder. Oral semaglutide is absorbed erratically compared with an injection, and the gut needs time to adjust to a daily rather than weekly exposure. Building up over eight to sixteen weeks is normal.
Switching from the Wegovy pill to Mounjaro
Going the other way is simpler, because oral semaglutide clears faster. The usual approach is to stop the tablets and take the first injection the following day, starting at 2.5mg — the standard tirzepatide starting dose — regardless of how high your tablet dose was.
- Take your final tablet as normal.
- Start Mounjaro 2.5mg the next day, and choose the weekday you want as your permanent injection day.
- Stay on 2.5mg for four weeks. This is a tolerance-building dose, not a treatment dose.
- Step up to 5mg at your next review if side effects are settled.
- Continue upwards no faster than every four weeks, guided by your clinician.
Some people worry that restarting at 2.5mg will undo their progress. In practice you are not starting from zero: appetite signalling stays partially suppressed through the changeover, and most people hold their weight steady during the first month rather than regaining.
What the first fortnight feels like
When switching is not the answer
If your reason for switching is side effects, a dose reduction on your current medicine often solves the problem faster than a change of molecule. If your reason is a plateau, it is worth checking protein intake, alcohol, sleep and whether you are still in a deficit before assuming the medicine has stopped working. And if your reason is cost, say so plainly to your clinician — the dose you are on, not the medicine you are on, is usually the bigger lever.
Switching is also not appropriate if you have had a serious reaction to either drug class, if you are pregnant or trying to conceive, or if you have a history of pancreatitis or medullary thyroid carcinoma. Those are conversations to have before any changeover is planned.
How ClariDay handles a switch
A prescriber reviews your current dose, how long you have been on it, your side-effect history and your weight trend, then writes a changeover plan with dates on it: last dose of the old medicine, first dose of the new one, the step-up schedule and the review point. You keep WhatsApp access to the clinical team throughout, which matters most in the first fortnight when something feels off and you want an answer the same day.
Check whether you can switchTwo minutes, no charge, reviewed by a prescriber.→
Questions people ask
Can I switch from Mounjaro to the Wegovy pill without a gap?▾
Not quite. Tirzepatide clears slowly, so the first tablet is normally taken seven days after the final injection — the day the next injection would have been due. That avoids overlapping two appetite-suppressing medicines while keeping the gap short enough that hunger does not fully return.
Will I regain weight while switching?▾
Most people hold steady rather than regain. Appetite suppression tapers off gradually rather than stopping overnight, and the new medicine begins working within the first week or two. A small fluctuation of two or three pounds, mostly fluid, is normal during the changeover.
Is there a dose conversion between tirzepatide and oral semaglutide?▾
No. There is no licensed or validated conversion between the two. They are different molecules acting on different receptors with different absorption, so a prescriber restarts you low on the new medicine and builds up, regardless of the dose you were taking before.
Which is more effective, the injection or the pill?▾
In trials tirzepatide produced the larger average loss — around 20.9% of body weight at the top dose over 72 weeks, against about 13.6% for the 25mg semaglutide tablet over 64 weeks. Those figures come from separate trials, and the two medicines have never been compared head to head. Individual results vary widely, and a medicine you can take consistently will usually beat a stronger one you cannot.
Do I have to start the injection at 2.5mg if I was on a high tablet dose?▾
Yes, in almost all cases. 2.5mg of tirzepatide is a tolerance-building dose designed to let the gut adjust, not a treatment dose. Skipping it is the main cause of avoidable nausea in the first month after switching.
Can I switch back if the new medicine does not suit me?▾
Yes. Switching back is common and is handled the same way: a planned changeover with a low starting dose and a review after four weeks. Tell your clinician early rather than stopping treatment on your own.
Will side effects be worse after a switch?▾
Usually they are milder than when you first started treatment, because your gut has already adapted to this class of medicine. Nausea, if it appears, tends to arrive in the second week and settle within a few days.
Can I switch while travelling?▾
It is better not to. A changeover asks for a predictable routine — a fixed injection day or a protected thirty-minute window before breakfast — and travel disrupts both. Plan the switch for a settled fortnight at home.
- About 20.9% average weight loss over 72 weeks in SURMOUNT-1
- Acts on two gut hormone pathways rather than one
- Prescriber-led dose ladder, reviewed every four weeks
- WhatsApp access to the clinical team seven days a week
References
- Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387:205-216.
- Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384:989-1002.
- Electronic Medicines Compendium. Mounjaro KwikPen — Summary of Product Characteristics.
- Electronic Medicines Compendium. Wegovy tablets — Summary of Product Characteristics.
- OASIS 4: oral semaglutide 25mg for weight management. N Engl J Med. 2025.
- SURMOUNT-5: tirzepatide versus semaglutide in obesity. N Engl J Med. 2025.
- Medicines and Healthcare products Regulatory Agency. GLP-1 receptor agonists: reports of misuse and safety advice.
